Discover and read the best of Twitter Threads about #lymsm

Most recents (6)

The many faces of plasma cell neoplasm, diagnostic challenges of the great imitator in #hemepath ➡️bit.ly/3B3jMC1 with @ljmedeirosMD & @ShiminHuMDPhD #mmsm #lymsm #pathtwitter #leusm
1) The small cell variant (mimicking B-cell lymphoma, particularly mantle cell lymphoma➡️CyclinD1 positive) #hemepath #pathtwitter
2) Cleaved cell variant (mimicking follicular lymphoma) #hemepath #pathtwitter
Read 13 tweets
So #twitterx doesn't throw me in Twitter jail, here are 10 #ASH21 abstracts...as HARRY POTTER characters.

I couldn't decide if I should rank based on "impactful" or "practice changing", so these are some that I think everyone should *read carefully*, and I tried to make it fun!
1. POLARIX = Severus Snape ash.confex.com/ash/2021/webpr… Why? Because of how controversial this is, and also this is a well done study. Should we change practice based on a drug without an OS or QOL benefit? I argue no. Nagini, kill. #lymsm
2. GRAAPH-2014 Study = Dudley Dursley ash.confex.com/ash/2021/webpr… Removing HiDAC from chemo in Ph+ ALL worsened outcomes. A cautionary tale that we can’t get greedy and we need RCT data like this as we “de-intensify” regimens in ALL with novel therapies like blin, TKIs, etc. #leusm
Read 12 tweets
Delighted to share our new study nature.com/articles/s4158… introducing PhasED-Seq out today @NatureBiotech.
A fantastic collaboration from @StanfordMedicine led by Dave_Kurtz & Joanne Soo with @max_diehn to help transform #cancer interception & monitoring by improving #LiquidBiopsy #ctDNA detection of #MRD.
For many cancers & nearly all currently available techniques, the impressive KM plots of #ctDNA #MRD immediately after definitive Rx w/ curative-intent unfortunately still miss ~50% of all events which occur in the MRD-negative subset, thus having modest NPV.
Read 21 tweets
Key takeaways from LOTIS-2 study leading to Loncastuximab approval in R/R DLBCL # Tweetorial #lymsm @ccarlostella @paolocaimiMD
Open-label; single arm; Single agent (important for efficacy data)
No exclusion for pri refrac; double hit NOT excluded (1/10)
thelancet.com/journals/lanon…
LOTIS-2 dosing of 150 µg/kg every 3 weeks (Q3W) for 2 doses followed by 75 µg/kg Q3W deduced from large phase 1 study in @BloodJournal (2/10)
pubmed.ncbi.nlm.nih.gov/33211842/
LOTIS 2; N enrolled = 145
ORR = 70 of 145 (48·3% [95% CI 39·9–56·7]);
35 had complete response and 35 had partial response.
Median DOR 10.3 mons
(3/10)
Read 10 tweets
First described by Dr. Burkitt as a sarcoma, this lymphoma is notorious for being rapidly fatal without treatment. Here is the remarkable history of the discovery of Burkitt’s lymphoma and the men and women behind it. #lymsm
Denis Burkitt was born on February 28th, 1911 in Enniskillen (Northern Ireland). He grew up in a Presbyterian family, and his faith influenced him greatly. He went to Trinity College in Dublin, with a goal to follow in father’s footsteps as an engineer.
He soon realized that engineering was not his calling. During that first year, he joined an evangelical group in College and was inspired by his uncle, a missionary physician stationed in Kenya, to pursue a career in medicine. He excelled in medicine, graduating in 1935.
Read 26 tweets
“Hodgkin’s disease” led to the earliest classification of lymphomas, which still stands today! If a lymphoma is not a Hodgkin’s then it’s a non-Hodgkin’s. Much has been written about the history of Hodgkin’s lymphoma. Here is a short visual walkthrough. #lymsm
Thomas Hodgkin, born on August 17 1798, was raised in a devout Quaker family. Because of his religion, he was unable to study medicine in England, which required people to be part of the Church of England.
Instead, he was allowed to rotate at Guy’s and met Sir Ashley Cooper who advices him to go to Edinburgh, Scotland. University of Edinburgh (pictured) was considered to be the best in the region.
Read 25 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!